Adient Medical

What Adient Medical does

Adient Medical is a private, pre-revenue medical device company founded in 2012 and headquartered in Pearland, Texas, that is developing the Adient Absorbable Vena Cava Filter — an absorbable inferior vena cava (IVC) filter constructed from polydioxanone (PDO), a polymer that has been FDA-approved for surgical applications for approximately 40 years. The filter is engineered to provide mechanical prophylaxis against pulmonary embolism (PE) for roughly 12 weeks during the transient risk window and then dissolve completely into carbon dioxide and water within approximately six months, eliminating the secondary retrieval procedures associated with conventional permanent metal IVC filters and the downstream complications of device fracture, embolization, IVC thrombosis, and organ perforation.

The company's target patient populations are adults at transient high risk for venous thromboembolism, specifically major trauma patients, patients undergoing major orthopedic procedures such as total knee replacement, and surgical ICU patients where systemic anticoagulation may be contraindicated. The device is delivered via a 12F catheter-based delivery system incorporating radiopaque markers for fluoroscopic visualization. Adient has progressed through first-in-human deployment in 2018 (8 patients, 9-month follow-up with no symptomatic PE), FDA IDE approval in 2021, and is currently enrolling its US pivotal study; it has also built a multi-jurisdiction patent portfolio covering the United States, Canada, China, Japan, Korea, Australia, Brazil, and the European Patent Office.

The business model is a single-product, single-use implantable hardware sale to hospitals and healthcare providers, to be executed through a planned direct enterprise sales force targeting interventional radiologists and vascular surgeons once FDA approval is obtained. The product is not commercially available and pricing has not been publicly disclosed. The company has raised approximately $14.5 million in equity financing (most recently in 2022 from Cordis and Ajax Health) plus $4.5 million in NIH grants, with strategic investors Becton Dickinson, Cordis, and Ajax Health providing cardiovascular industry validation; total disclosed funding rounds across grant, equity, and accelerator sources exceed $20 million when accounting for Broadview Ventures (2017), Green Park & Golf Ventures and Houston Angel Network (2016), and others.

Name

Adient Medical

Legal name

Adient Medical, Inc.

Website

https://adientmedical.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

Adient Medical is a pre-revenue medical device company developing the first fully absorbable IVC filter that dissolves within roughly six months to prevent pulmonary embolism without requiring retrieval. Its polydioxanone-based filter targets trauma, orthopedic, and surgical ICU patients served via interventional radiologists.

Ownership category

akta.pro rank

Product category

Absorbable Inferior Vena Cava (IVC) Filters

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

• Absorbable medical devices
• Inferior vena cava filter
• Pulmonary embolism prevention
• Vascular filters
• Interventional radiology devices

Headquarters

HQ city

Pearland

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Once FDA approved, Adient Medical will generate revenue through the sale of its absorbable IVC filters to hospitals and healthcare providers. The device is a single-use implantable medical device for temporary prevention of pulmonary embolism.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Adient Medical is developing the Adient Absorbable Vena Cava Filter, a single-use catheter-delivered IVC filter made of polydioxanone (PDO) that mechanically captures blood clots to prevent pulmonary embolism for approximately 12 weeks and then completely dissolves into carbon dioxide and water within about 6 months. The product is intended for temporary prevention of pulmonary embolism in patients with transient high risk for venous thromboembolism. The device is not yet commercially available and is undergoing a US pivotal clinical study under FDA IDE approval.

Product overview

Adient Medical is a single-product medical device company focused on the development of one core product: the Adient Absorbable Vena Cava Filter. This absorbable vascular filter is designed for the temporary prevention of pulmonary embolism (PE) in at-risk patients. Unlike conventional metal IVC filters that require retrieval procedures, the Adient filter is made of polydioxanone, maintains strength during the protection period, and then naturally absorbs into the body after approximately 6 months, eliminating the need for removal procedures.

Differentiator

Problem solved

Functional benefit

Products and services

• Adient Absorbable Vena Cava Filter Single-use catheter-delivered absorbable inferior vena cava (IVC) filter made of polydioxanone (PDO) that captures blood clots traveling to the lungs for approximately 12 weeks and then fully dissolves into carbon dioxide and water within about 6 months. Designed for temporary prevention of pulmonary embolism in patients with transient high risk for venous thromboembolism, including major trauma, major orthopedic surgery (e.g., total knee replacement), and surgical ICU patients. Targets interventional radiologists and vascular surgeons in hospital settings.

Quantifiable outcome

• Filter maintains sufficient strength throughout 12-week protection period while acute blood clots dissolve within approximately 3 weeks
• +3 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Synchrony LabscoreStrategic or Co-development Partner · 1 January 2013Synchrony Labs conducted a randomized controlled study comparing the absorbable filter to a leading metal IVC filter in a porcine model, demonstrating safety and efficacy.
• University of Texas MD Anderson Cancer CentercoreStrategic or Co-development PartnerCollaborative partnership with University of Texas MD Anderson Cancer Center for development of the absorbable filter technology. The late Michael Wallace MD (Chairman of Interventional Radiology) helped form the intradisciplinary team including interventional radiologist Steven Huang MD, who together with founder Mitch Eggers first demonstrated feasibility of the absorbable filter concept in 2013.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cook Medical: Cook Medical is a leading manufacturer of IVC filters including the Celect and Tulip retrievable filters, directly competing with Adient in the same product category and serving the same interventional radiology and vascular surgery hospital customers.
• Argon Medical Devices: Argon Medical manufactures the Option Elite retrievable IVC filter, competing directly with Adient in the same temporary pulmonary embolism prevention indication for hospital-based interventional radiology customers.

Broad incumbents

• Becton Dickinson (BD): BD acquired Bard and markets the Denali and Recovery IVC filters. As a major diversified medical device incumbent, BD is a broad competitor in the IVC filter space and is also an Adient investor, making it a directly comparable large player in the same category.
• Cordis: Cordis manufactures the OptEase and TrapEase IVC filters and is a major cardiovascular device incumbent. As lead investor in Adient's 2022 round, Cordis is a broad incumbent peer and potential acquirer/distribution partner for Adient's absorbable filter.
• Boston Scientific: Boston Scientific is a diversified interventional device incumbent with adjacent vascular franchises and active bioabsorbable polymer research programs. It serves the same interventional radiology and vascular surgery customers as Adient and represents a potential strategic acquirer of absorbable IVC filter technology.

Emerging players

• ALN Implants Chirurgicaux: ALN is a European-based manufacturer of the ALN Optional vena cava filter, a smaller specialist player in the retrievable IVC filter segment and directly comparable to Adient in terms of product focus and customer profile.
• Penumbra: Penumbra is a vascular thrombectomy and embolization device company whose Indigo and Lightning product lines address adjacent clot management applications, making it a comparable emerging player in the interventional vascular space serving the same hospital call point.
• Inari Medical: Inari Medical develops interventional thrombectomy devices (FlowTriever, ClotTriever) for venous thromboembolism, addressing the same underlying PE/VTE patient population as Adient's filter and serving the same interventional call point in hospitals.

Regional players

• Mermaid Medical: Mermaid Medical is a Denmark-based distributor and developer of vascular filters and interventional radiology devices in European and select international markets, providing a regional peer comparison for IVC filter commercialization outside the US.
• Braile Biomédica: Braile Biomédica is a Brazilian medical device manufacturer that develops and markets vascular and cardiovascular devices, including products in the venous intervention space; a regional peer for Adient in the Latin American market where Adient already has an issued patent and first-in-human experience in Mexico.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/1639335702964195
• LinkedInlinkedin.com/company/adient-medical-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds7 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adient Medical